Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis

References

• Firestein, GS. Etiology and pathogenesis of rheumatoid arthritis. WN Kelley, Harris, ED, Ruddy, S,Sledge, CB, . Textbook of rheumatology. Philadelphia: WB Saunders Company, 1997:851–97.
   Google Scholar
• Klimiuk PA, Goronzy JJ, Bjornsson J, Beckenbaugh RD, Weyand CM. Tissue cytokine patterns distinguish variants of rheumatoid synovitis. Am J Pathol 1997; 151: 1311–19
   PubMed Web of Science ®Google Scholar
• Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000; 43: 2619–33
   PubMed Web of Science ®Google Scholar
• Blann AD, Herrick A, Jayson MIV. Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Br J Rheumatol 1995; 34: 814–19
   PubMedGoogle Scholar
• McMurray RW. Adhesion molecules in autoimmune disease. Semin Arthritis Rheum 1996; 25: 215–34
   PubMed Web of Science ®Google Scholar
• Mojcik CF, Shevach EM. Adhesion molecules: a rheumatologic perspective. Arthritis Rheum 1997; 40: 991–1004
   PubMed Web of Science ®Google Scholar
• Tokuhira M, Hosaka S, Volin MV, Haines GK, 3rd, Katschke KJ, Jr, Kim S, et al. Soluble vascular cell adhesion molecule 1 mediation of monocyte chemotaxis in rheumatoid arthritis. Arthritis Rheum 2000; 43: 1122–33
   PubMed Web of Science ®Google Scholar
• Brenchley PEC. Antagonising angiogenesis in rheumatoid arthritis. Ann Rheum Dis 2001; 60: iii71–4
   PubMed Web of Science ®Google Scholar
• Paleolog EM. Angiogenesis: a critical process in the pathogenesis of RA – a role for VEGF?. Br J Rheumatol 1996; 35: 917–20
   PubMedGoogle Scholar
• Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995; 376: 517–19
   PubMed Web of Science ®Google Scholar
• Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, et al. Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis 2002; 61: 804–9
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478–86
   PubMed Web of Science ®Google Scholar
• van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, et al. Add Enbrel or Replace Methotrexate Study Investigators. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006; 65: 1478–83
   PubMed Web of Science ®Google Scholar
• Aggarwal A, Panda S, Misra R. Effect of etanercept on matrix metalloproteinases and angiogenic vascular endothelial growth factor: a time kinetic study. Ann Rheum Dis 2004; 63: 891–2
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24
   PubMed Web of Science ®Google Scholar
• Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 1949; 140: 659–62
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–8
   PubMed Web of Science ®Google Scholar
• Schmitt-Sody M, Metz P, Klose A, Gottschalk O, Zysk S, Hausdorf J, et al. In vivo interactions of platelets and leucocytes with the endothelium in murine antigen-induced arthritis: the role of P-selectin. Scand J Rheumatol 2007; 36: 311–19
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Haines GK, Lin TR, Harlow LA, Goerdt S, Rayan G, et al. Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and disease human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum 1994; 37: 221–31
   PubMed Web of Science ®Google Scholar
• Tak PP, Thurkow EW, Daha MR, Kluin PM, Smeets TJ, Meinders AE, et al. Expression of adhesion molecules in early rheumatoid synovial tissue. Clin Immunol Immunopathol 1995; 77: 236–42
   PubMedGoogle Scholar
• Kuryliszyn-Moskal A, Bernacka K, Klimiuk PA. Circulating intercellular adhesion molecule 1 in rheumatoid arthritis – relationship to systemic vasculitis and microvascular injury in nailfold capillary microscopy. Clin Rheumatol 1996; 15: 367–73
   PubMed Web of Science ®Google Scholar
• Littler AJ, Buckley CD, Wordsworth P, Collins I, Martinson J, Simmons DL. A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br J Rheumatol 1997; 36: 164–9
   PubMedGoogle Scholar
• Nassonov EL, Samsonov MY, Chichasova NV, Nikiphorova EL, Tilz GP, Demel U, et al. Soluble adhesion molecules in rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 808–10
   PubMed Web of Science ®Google Scholar
• Klimiuk PA, Fiedorczyk M, Sierakowski S, Chwiecko J. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis. Scand J Rheumatol 2007; 36: 345–50
   PubMed Web of Science ®Google Scholar
• Carter RA, Wicks IP. Vascular cell adhesion molecule 1 (CD106). A multifaceted regulator of joint inflammation. Arthritis Rheum 2001; 44: 985–94
   PubMed Web of Science ®Google Scholar
• Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1258–65
   PubMed Web of Science ®Google Scholar
• Klimiuk PA, Sierakowski S, Domysławska I, Fiedorczyk M, Chwiecko J. Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. Arch Immunol Ther Exp (Warsz) 2004; 52: 36–42
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, et al. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 373–9
   PubMed Web of Science ®Google Scholar
• Levälampi T, Honkanen V, Lahdenne P, Nieminen R, Hakala M, Moilanen E. Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis. Scand J Rheumatol 2007; 36: 189–93
   PubMed Web of Science ®Google Scholar
• To SST, Newman PM, Hyland VJ, Robinson BG, Schrieber L. Regulation of adhesion molecule expression by human synovial microvascular endothelial cells in vitro. Arthritis Rheum 1996; 39: 467–77
   PubMed Web of Science ®Google Scholar
• Ferrara N. Leukocyte adhesion. Missing link in angiogenesis. Nature 1995; 376: 467
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Paleolog E, Charles P, Ballara S, Brennan FM, et al. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis 1999; 58(Suppl 1)I56–60
   PubMedGoogle Scholar
• Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1258–65
   PubMed Web of Science ®Google Scholar
• Harada M, Mitsuyama K, Yoshida H, Sakisaka S, Taniguchi E, Kawaguchi T, et al. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 1998; 27: 377–80
   PubMed Web of Science ®Google Scholar
• Lee SS, Joo YS, Kim WU, Min DJ, Min JK, Park SH, et al. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 2001; 19: 321–4
   PubMed Web of Science ®Google Scholar
• Cush JJ, Rothlein R, Lindsley HB, Mainolfi EA, Lipsky PE. Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum 1993; 36: 1098–102
   PubMed Web of Science ®Google Scholar
• Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum 1996; 39: 1082–91
   PubMed Web of Science ®Google Scholar